Other immunotherapies for breast cancer, including cytotoxic T-lymphocyte-associated antigen 4 or CTLA-4, tumor-infiltrating lymphocytes, and tumor vaccines, have also achieved relatively good results in the research setting and may pave the way for more breast cancer treatments that can be applied in the clinical setting (52). This evidence concerns the gene CTLA4 and breast carcinoma.